Vimarsana
Biggest News Aggregation in the World

Page 12 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

EQS-News: Immunic, Inc.: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis - Vimarsana News

EQS-News: Immunic, Inc.: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe

Immunic, Inc. (NASDAQ:IMUX) Receives $22.00 Consensus Price Target from Analysts - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) Receives $22.00 Consensus Price Target from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on […]

EQS-News: Immunic to Participate in Investor and Scientific Conferences in March - Vimarsana News

EQS-News: Immunic to Participate in Investor and Scientific Conferences in March

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in March 02.03.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Investor and Scientific Conferences in March NEW YOR...

Immunic to Participate in Investor and Scientific Conferences in March - Vimarsana News

Immunic to Participate in Investor and Scientific Conferences in March

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update - Vimarsana News

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Immunic, Inc. (NASDAQ: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...